ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epitope-specific) immunotherapy, ImmusanT is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.
We are now recruiting for clinical trials in celiac disease.
February 22, 2017
ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease
December 1, 2016
Genetic Engineering & Biotechnology News: Immunotherapy Encompasses More Than Immuno-oncology
October 12, 2016
Gastroenterology & Endoscopy News: Novel Strategies for Treatment Of Celiac Disease Advance
One Kendall Square
Suite B2004
Cambridge, MA 02139
Phone: 617-299-8399